Floatz logo

(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4

Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan

Seoul National University Bundang HospitalmixturePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 is also rated in:

MSI-L/MSSDormant
B
Indicative ·
63 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
61 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →